Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

Real-world effectiveness of fulvestrant monotherapy as first endocrine treatment in patients with metastatic breast cancer.

Skinner KE, Olufade T, Walker MS, Schwartzberg LS.

Breast J. 2019 Sep 17. doi: 10.1111/tbj.13492. [Epub ahead of print]

PMID:
31531938
2.

Real-world treatment patterns among patients with unresected stage III non-small-cell lung cancer.

Ryan KJ, Skinner KE, Fernandes AW, Punekar RS, Pavilack M, Walker MS, VanderWalde NA.

Future Oncol. 2019 Sep;15(25):2943-2953. doi: 10.2217/fon-2018-0939. Epub 2019 Apr 30.

3.

Examining Professional Identity Formation Through the Ancient Art of Mask-Making.

Stephens MB, Bader KS, Myers KR, Walker MS, Varpio L.

J Gen Intern Med. 2019 Jul;34(7):1113-1115. doi: 10.1007/s11606-019-04954-3. No abstract available.

PMID:
30891691
4.

Treatment patterns, clinical outcomes, health resource utilization, and cost in patients with BRCA-mutated metastatic breast cancer treated in community oncology settings.

Houts AC, Olufade T, Shenolikar R, Walker MS, Schwartzberg LS.

Cancer Treat Res Commun. 2019;19:100121. doi: 10.1016/j.ctarc.2019.100121. Epub 2019 Feb 6.

5.

OSIRIS-REx Contamination Control Strategy and Implementation.

Dworkin JP, Adelman LA, Ajluni T, Andronikov AV, Aponte JC, Bartels AE, Beshore E, Bierhaus EB, Brucato JR, Bryan BH, Burton AS, Callahan MP, Castro-Wallace SL, Clark BC, Clemett SJ, Connolly HC Jr, Cutlip WE, Daly SM, Elliott VE, Elsila JE, Enos HL, Everett DF, Franchi IA, Glavin DP, Graham HV, Hendershot JE, Harris JW, Hill SL, Hildebrand AR, Jayne GO, Jenkens RW Jr, Johnson KS, Kirsch JS, Lauretta DS, Lewis AS, Loiacono JJ, Lorentson CC, Marshall JR, Martin MG, Matthias LL, McLain HL, Messenger SR, Mink RG, Moore JL, Nakamura-Messenger K, Nuth JA 3rd, Owens CV, Parish CL, Perkins BD, Pryzby MS, Reigle CA, Righter K, Rizk B, Russell JF, Sandford SA, Schepis JP, Songer J, Sovinski MF, Stahl SE, Thomas-Keprta K, Vellinga JM, Walker MS.

Space Sci Rev. 2018 Feb;214(1). pii: 19. doi: 10.1007/s11214-017-0439-4. Epub 2017 Dec 13.

6.

Real-world outcomes in patients with unresected stage III non-small cell lung cancer.

Ryan KJ, Skinner KE, Fernandes AW, Punekar RS, Pavilack M, Walker MS, VanderWalde NA.

Med Oncol. 2019 Jan 31;36(3):24. doi: 10.1007/s12032-019-1249-1.

PMID:
30706218
7.

Treatment Patterns and Outcomes in Stage IV Bladder Cancer in a Community Oncology Setting: 2008-2015.

Fisher MD, Shenolikar R, Miller PJ, Fenton M, Walker MS.

Clin Genitourin Cancer. 2018 Dec;16(6):e1171-e1179. doi: 10.1016/j.clgc.2018.07.025. Epub 2018 Aug 11.

8.

Effectiveness Outcomes in Patients With Recurrent or Refractory Head and Neck Cancers: Retrospective Analysis of Data From a Community Oncology Database.

Fisher MD, Fernandes AW, Olufade TO, Miller PJ, Walker MS, Fenton M.

Clin Ther. 2018 Sep;40(9):1522-1537. doi: 10.1016/j.clinthera.2018.07.016. Epub 2018 Aug 25.

9.

Treatment Outcomes in Patients with Metastatic Neuroendocrine Tumors: a Retrospective Analysis of a Community Oncology Database.

Fisher MD, Pulgar S, Kulke MH, Mirakhur B, Miller PJ, Walker MS, Schwartzberg LS.

J Gastrointest Cancer. 2018 Aug 18. doi: 10.1007/s12029-018-0160-x. [Epub ahead of print]

PMID:
30121904
10.

'Master My Demons': art therapy montage paintings by active-duty military service members with traumatic brain injury and post-traumatic stress.

Berberian M, Walker MS, Kaimal G.

Med Humanit. 2018 Aug 4. pii: medhum-2018-011493. doi: 10.1136/medhum-2018-011493. [Epub ahead of print]

PMID:
30077986
12.

Pretreatment costs of care and time to initial treatment for patients with cancer of unknown primary.

Walker MS, Weinstein L, Luo R, Marino I.

J Comp Eff Res. 2018 Jun;7(6):523-533. doi: 10.2217/cer-2017-0104. Epub 2018 Jun 1.

PMID:
29855191
13.

Patient Characteristics and Costs in Recurrent or Refractory Head and Neck Cancer: Retrospective Analysis of a Community Oncology Database.

Fisher MD, Fernandes AW, Olufade TO, Miller PJ, Walker MS, Fenton M.

Clin Ther. 2018 Apr;40(4):562-573. doi: 10.1016/j.clinthera.2018.02.010. Epub 2018 Mar 9.

14.

Treatment Patterns and Outcomes in Patients with KRAS Wild-Type Metastatic Colorectal Cancer Treated in First Line with Bevacizumab- or Cetuximab-Containing Regimens.

Houts AC, Ogale S, Sommer N, Satram-Hoang S, Walker MS.

J Gastrointest Cancer. 2019 Mar;50(1):69-77. doi: 10.1007/s12029-017-0027-6.

PMID:
29168112
15.

Effect of Brain Metastasis on Patient-Reported Outcomes in Advanced NSCLC Treated in Real-World Community Oncology Settings.

Walker MS, Wong W, Ravelo A, Miller PJE, Schwartzberg LS.

Clin Lung Cancer. 2018 Mar;19(2):139-147. doi: 10.1016/j.cllc.2017.10.003. Epub 2017 Oct 13.

PMID:
29103883
16.

Progression-Free Survival in Patients Receiving Chemotherapy Alone (C) or Chemotherapy with Bevacizumab (CB) for First-Line Treatment of KRAS Mutant Metastatic Colorectal Cancer in Community Oncology Settings.

Houts AC, Ogale S, Zafar Y, Hubbard JM, Satram-Hoang S, Sommer N, Walker MS.

J Gastrointest Cancer. 2019 Mar;50(1):16-22. doi: 10.1007/s12029-017-0017-8.

PMID:
29058260
17.

Healthcare costs in patients with advanced non-small cell lung cancer and disease progression during targeted therapy: a real-world observational study.

Skinner KE, Fernandes AW, Walker MS, Pavilack M, VanderWalde A.

J Med Econ. 2018 Feb;21(2):192-200. doi: 10.1080/13696998.2017.1389744. Epub 2017 Oct 18.

PMID:
29041833
18.

Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma.

Samuels BL, Chawla SP, Somaiah N, Staddon AP, Skubitz KM, Milhem MM, Kaiser PE, Portnoy DC, Priebat DA, Walker MS, Stepanski EJ.

Cancer. 2017 Dec 1;123(23):4640-4647. doi: 10.1002/cncr.30926. Epub 2017 Aug 18.

20.

Active-duty military service members' visual representations of PTSD and TBI in masks.

Walker MS, Kaimal G, Gonzaga AML, Myers-Coffman KA, DeGraba TJ.

Int J Qual Stud Health Well-being. 2017 Dec;12(1):1267317. doi: 10.1080/17482631.2016.1267317.

21.

A randomized controlled trial of directive and nondirective smoking cessation coaching through an employee quitline.

Sumner W 2nd, Walker MS, Highstein GR, Fischer I, Yan Y, McQueen A, Fisher EB.

BMC Public Health. 2016 Jul 11;16:550. doi: 10.1186/s12889-016-3202-y.

22.

Burden of symptoms associated with development of metastatic bone disease in patients with breast cancer.

Cleeland C, von Moos R, Walker MS, Wang Y, Gao J, Chavez-MacGregor M, Liede A, Arellano J, Balakumaran A, Qian Y.

Support Care Cancer. 2016 Aug;24(8):3557-65. doi: 10.1007/s00520-016-3154-x. Epub 2016 Mar 29.

23.

Analysis of the psychological impact of cancer-related symptoms on patients with non-small cell lung cancer.

Walker MS, Pohl GM, Houts AC, Peltz G, Miller PJE, Schwartzberg LS, Stepanski EJ, Marciniak M.

Psychooncology. 2017 Jun;26(6):755-762. doi: 10.1002/pon.4071. Epub 2016 Jan 20.

PMID:
26790987
24.

Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice.

Mitchell AP, Harrison MR, Walker MS, George DJ, Abernethy AP, Hirsch BR.

J Oncol Pract. 2015 Nov;11(6):491-7. doi: 10.1200/JOP.2015.004929. Epub 2015 Sep 1.

PMID:
26330533
25.

Treatment patterns and clinical effectiveness in metastatic castrate resistant prostate cancer after first-line docetaxel.

Houts AC, Hennessy D, Walker MS, Nicacio L, Thompson SF, Miller PJ, Somer BG.

J Community Support Oncol. 2014 Sep;12(9):321-8. doi: 10.12788/jcso.0072.

PMID:
25848909
26.

Treatment Patterns and Health Resource Utilization Among Patients Diagnosed With Early Stage Resected Non-Small Cell Lung Cancer at US Community Oncology Practices.

Buck PO, Saverno KR, Miller PJ, Arondekar B, Walker MS.

Clin Lung Cancer. 2015 Nov;16(6):486-95. doi: 10.1016/j.cllc.2014.12.010. Epub 2014 Dec 31.

27.

Use of "Real-World" data to describe adverse events during the treatment of metastatic renal cell carcinoma in routine clinical practice.

Hirsch BR, Harrison MR, George DJ, Walker MS, Chen C, Korytowsky B, Stepanski E, Abernethy AP.

Med Oncol. 2014 Sep;31(9):156. doi: 10.1007/s12032-014-0156-8. Epub 2014 Aug 14.

PMID:
25115744
28.

Glycemic variability in nondiabetic morbidly obese persons: results of an observational study and review of the literature.

Salkind SJ, Huizenga R, Fonda SJ, Walker MS, Vigersky RA.

J Diabetes Sci Technol. 2014 Sep;8(5):1042-7. doi: 10.1177/1932296814537039. Epub 2014 May 29. Review.

29.

Treatment patterns and outcomes among patients with metastatic melanoma treated in community practice.

Walker MS, Reyes C, Kerr J, Satram-Hoang S, Stepanski EJ.

Int J Dermatol. 2014 Nov;53(11):e499-506. doi: 10.1111/ijd.12427. Epub 2014 Mar 6.

PMID:
24602078
30.

Early treatment discontinuation and switching in first-line metastatic breast cancer: the role of patient-reported symptom burden.

Walker MS, Masaquel AS, Kerr J, Lalla D, Abidoye O, Houts AC, Schwartzberg LS.

Breast Cancer Res Treat. 2014 Apr;144(3):673-81. doi: 10.1007/s10549-014-2892-z. Epub 2014 Mar 5.

PMID:
24596047
31.

Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies.

Mahadevan D, Sutton GR, Arteta-Bulos R, Bowden CJ, Miller PJ, Swart RE, Walker MS, Haluska P, Munster PN, Marshall J, Hamid O, Kurzrock R.

Cancer Chemother Pharmacol. 2014 Mar;73(3):467-73. doi: 10.1007/s00280-013-2372-x. Epub 2014 Jan 4.

PMID:
24390424
32.

Real-world outcomes in metastatic renal cell carcinoma: insights from a Joint Community-Academic Registry.

Harrison MR, Hirsch BR, George DJ, Walker MS, Chen C, Korytowsky B, Stepanski E, Abernethy AP.

J Oncol Pract. 2014 Mar;10(2):e63-72. doi: 10.1200/JOP.2013.001180. Epub 2013 Nov 26.

PMID:
24281152
33.

Phase II trial of fulvestrant with metronomic capecitabine for postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.

Schwartzberg LS, Wang G, Somer BG, Blakely LJ, Wheeler BM, Walker MS, Stepanski EJ, Houts AC.

Clin Breast Cancer. 2014 Feb;14(1):13-9. doi: 10.1016/j.clbc.2013.09.003. Epub 2013 Sep 27.

PMID:
24268206
34.

Coaching intervention as a strategy for minority recruitment to cancer clinical trials.

Fracasso PM, Goodner SA, Creekmore AN, Morgan HP, Foster DM, Hardmon AA, Engel SJ, Springer BC, Mathews KJ, Fisher EB, Walker MS.

J Oncol Pract. 2013 Nov;9(6):294-9. doi: 10.1200/JOP.2013.000982. Epub 2013 Oct 15.

35.

Willingness to pay to prevent chemotherapy induced nausea and vomiting among patients with breast, lung, or colorectal cancer.

Miller PJ, Balu S, Buchner D, Walker MS, Stepanski EJ, Schwartzberg LS.

J Med Econ. 2013 Oct;16(10):1179-89. doi: 10.3111/13696998.2013.832257. Epub 2013 Sep 5.

PMID:
23919632
36.

Prospective observational comparison of clinical outcomes between african-american and caucasian patients receiving second-line treatment with pemetrexed for advanced non-small-cell lung cancer.

Pennella E, Obasaju CK, Pohl G, Peltz G, Girvan AC, Winfree KB, Martinez B, Marciniak M, Walker MS, Stepanski E, Schwartzberg LS, Adjei A.

Clin Lung Cancer. 2013 Nov;14(6):726-35. doi: 10.1016/j.cllc.2013.06.011. Epub 2013 Jul 31.

PMID:
23910068
37.

Spirit-guided care: Christian nursing for the whole person.

Murphy LS, Walker MS.

J Christ Nurs. 2013 Jul-Sep;30(3):144-52; quiz 153-4.

PMID:
23862280
38.

"Real world" treatment of metastatic renal cell carcinoma in a joint community-academic cohort: progression-free survival over three lines of therapy.

Harrison MR, George DJ, Walker MS, Chen C, Korytowsky B, Kirkendall DT, Stepanski EJ, Abernethy AP.

Clin Genitourin Cancer. 2013 Dec;11(4):441-50. doi: 10.1016/j.clgc.2013.05.002. Epub 2013 Jul 12.

PMID:
23856102
39.

Heterogeneity of responses to real-time continuous glucose monitoring (RT-CGM) in patients with type 2 diabetes and its implications for application.

Fonda SJ, Salkind SJ, Walker MS, Chellappa M, Ehrhardt N, Vigersky RA.

Diabetes Care. 2013 Apr;36(4):786-92. doi: 10.2337/dc12-1225. Epub 2012 Nov 19.

40.

Relationship between incidence of fracture and health-related quality-of-life in metastatic breast cancer patients with bone metastases.

Walker MS, Miller PJ, Namjoshi M, Houts AC, Stepanski EJ, Schwartzberg LS.

J Med Econ. 2013;16(1):179-89. doi: 10.3111/13696998.2012.737883. Epub 2012 Oct 23.

PMID:
23043593
41.

A progressive step toward healthcare equality.

Gallagher CM, Hernandez CL, Walker MS.

Healthc Exec. 2012 Sep-Oct;27(5):54-6. No abstract available.

PMID:
22973795
42.

Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma.

Tillmanns TD, Lowe MP, Walker MS, Stepanski EJ, Schwartzberg LS.

Gynecol Oncol. 2013 Feb;128(2):221-8. doi: 10.1016/j.ygyno.2012.08.039. Epub 2012 Sep 5.

PMID:
22960352
43.

Symptom burden & quality of life among patients receiving second-line treatment of metastatic colorectal cancer.

Walker MS, Pharm EY, Kerr J, Yim YM, Stepanski EJ, Schwartzberg LS.

BMC Res Notes. 2012 Jun 20;5:314. doi: 10.1186/1756-0500-5-314.

44.

The association of rash severity with overall survival: findings from patients receiving erlotinib for pancreatic cancer in the community setting.

Stepanski EJ, Reyes C, Walker MS, Satram-Hoang S, Leon L, Wojtowicz-Praga S, Miller PJ, Houts AC, Schwartzberg LS.

Pancreas. 2013 Jan;42(1):32-6. doi: 10.1097/MPA.0b013e318254f19a.

PMID:
22699203
45.

Effect of ionic liquid pretreatment on the chemical composition, structure and enzymatic hydrolysis of energy cane bagasse.

Qiu Z, Aita GM, Walker MS.

Bioresour Technol. 2012 Aug;117:251-6. doi: 10.1016/j.biortech.2012.04.070. Epub 2012 Apr 26.

PMID:
22617034
46.

Mobile phone-based video messages for diabetes self-care support.

Bell AM, Fonda SJ, Walker MS, Schmidt V, Vigersky RA.

J Diabetes Sci Technol. 2012 Mar 1;6(2):310-9.

47.

Phase II multicenter trial of albumin-bound paclitaxel and capecitabine in first-line treatment of patients with metastatic breast cancer.

Schwartzberg LS, Arena FP, Mintzer DM, Epperson AL, Walker MS.

Clin Breast Cancer. 2012 Apr;12(2):87-93. doi: 10.1016/j.clbc.2011.10.004. Epub 2011 Dec 6.

PMID:
22154117
48.

Short- and long-term effects of real-time continuous glucose monitoring in patients with type 2 diabetes.

Vigersky RA, Fonda SJ, Chellappa M, Walker MS, Ehrhardt NM.

Diabetes Care. 2012 Jan;35(1):32-8. doi: 10.2337/dc11-1438. Epub 2011 Nov 18.

49.

The effect of real-time continuous glucose monitoring on glycemic control in patients with type 2 diabetes mellitus.

Ehrhardt NM, Chellappa M, Walker MS, Fonda SJ, Vigersky RA.

J Diabetes Sci Technol. 2011 May 1;5(3):668-75.

50.

Retrospective study of the effect of disease progression on patient reported outcomes in HER-2 negative metastatic breast cancer patients.

Walker MS, Hasan M, Yim YM, Yu E, Stepanski EJ, Schwartzberg LS.

Health Qual Life Outcomes. 2011 Jun 20;9:46. doi: 10.1186/1477-7525-9-46.

Supplemental Content

Loading ...
Support Center